surmount-1 tirzepatide weight loss non-diabetic SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes Tirzepatide and blood pressure reduction:

The oral GLP-1 currently available: the Wegovy pill The Wegovy pill (oral semaglutide 25 mg) was approved by the FDA in December 2025 and launched in the US in January 2026

Reviews from this user segment tend to be positive initially but transition to disappointment as expectations grow

Studies show it can lead to weight loss of 5% to 20%, depending on the dose

You may experience painful stool passing and constipation

Excess body fat can interfere with the body's ability to process fats and sugars efficiently, leading to abnormal lipid levels

Uses radiofrequency, laser, and vacuum therapy together for visible results